decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / CERTAIN_DRUGS_DISTRIBUTED_BY_THE_NATIONAL_CANCER_INSTITUTE
Subscribe or sign in to view the full article.
Article Overview
This National Coverage Determinations Manual article addresses coverage policy for certain drugs distributed by the National Cancer Institute for terminally ill cancer patients. It explains the general framework for Group C drugs, the kinds of administrative requirements associated with access and reporting, and how coverage is considered when these drugs are used. The content is relevant to providers, coders, billing staff, and compliance teams working with oncology-related Medicare coverage policy.
Why This Topic Matters
It helps readers understand when NCI-distributed cancer drugs may be considered covered under Medicare policy and what administrative oversight surrounds their use. This is important for oncology practices and hospital billing/compliance workflows that handle coverage verification and related documentation.
What You Will Learn
- The general Medicare coverage context for certain NCI-distributed cancer drugs
- The role of the National Cancer Institute and related federal oversight
- The administrative requirements associated with physician access and drug distribution
- How coverage is generally considered when these drugs are used in patient care
- Where to direct follow-up questions about specific coverage concerns
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Oncology providers
- Hospital utilization review staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com